These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 815025)

  • 1. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].
    Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
    C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
    Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J
    Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl.
    Auclair C; Pierre A; Voisin E; Pepin O; Cros S; Colas C; Saucier JM; Verschuere B; Gros P; Paoletti C
    Cancer Res; 1987 Dec; 47(23):6254-61. PubMed ID: 3677074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemia.
    Paoletti C; Cros S; Xuong ND; Lecointe P; Moisand A
    Chem Biol Interact; 1979 Apr; 25(1):45-58. PubMed ID: 466727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some antitumor derivatives of ellipticine deprived of mutagenic properties.
    Lecointe P; Lesca P; Cros S; Paoletti C
    Chem Biol Interact; 1978 Jan; 20(1):113-21. PubMed ID: 630641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
    Anderson G; Clavel M; Smyth J; Giaccone G; Gracia M; Planting AS; Dalesio O; Kirkpatrick A; McVie G
    Eur J Cancer Clin Oncol; 1989 May; 25(5):909-10. PubMed ID: 2737223
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)].
    Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Yuong ; Le Pecq JB; Paoletti C
    Nouv Presse Med; 1979 Apr; 8(18):1495-8. PubMed ID: 471724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Syntheses designed to produce 8-amino ellipticine. Synthesis and pharmacological properties of 8-nitro ellipticine].
    Gansser C; Lévque X; Plat M; Viel C
    Farmaco Sci; 1982 May; 37(5):283-97. PubMed ID: 7095141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of 9-hydroxyellipticine (NSC 210717) ON L1210 mouse leukemia and the effect of route of injection.
    Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Cros S; Paoletti C
    Cancer Res; 1976 Sep; 36(9 pt.1):3067-76. PubMed ID: 975074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor cell growth in vitro and in vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles.
    Sautereau AM; Cros S; Tocanne JF
    Biopharm Drug Dispos; 1986; 7(4):357-71. PubMed ID: 3768491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [9-Nitro- and 9-amino-ellipticines and derivatives: synthesis and pharmacologic properties].
    Gansser C; Viel C; Malvy C; Cros S
    Farmaco Sci; 1980 Nov; 35(11):887-95. PubMed ID: 7450021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution and absorption of the antineoplastic agent ellipticine.
    Rahman A; Cradock JC; Davignon JP
    J Pharm Sci; 1978 May; 67(5):611-4. PubMed ID: 641792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers.
    Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Xuong N; Le Pecq JB; Paoletti C
    Eur J Cancer (1965); 1978 Feb; 14(2):205-6. PubMed ID: 342255
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
    Juret P; Heron JF; Couette JE; Delozier T; Le Talaer JY
    Cancer Treat Rep; 1982 Nov; 66(11):1909-16. PubMed ID: 7139636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer.
    Juret P; Le Talaer Y; Couette JE; Delozier T
    Eur J Cancer (1965); 1980; Suppl 1():277-9. PubMed ID: 7032940
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of membrane potential on the cellular uptake of 2-N-methyl-ellipticinium by L1210 cells.
    Charcosset JY; Jacquemin-Sablon A; Le Pecq JB
    Biochem Pharmacol; 1984 Jul; 33(14):2271-5. PubMed ID: 6466349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study.
    Tura S; Mandelli F; Mazza P; Cimino G; Anselmo AP; Amadori S
    Chemioterapia; 1984 Apr; 3(2):79-82. PubMed ID: 6532540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)].
    Juret P; Couette JE; Delozier T; Le Talaer JY
    Bull Cancer; 1981; 68(3):224-31. PubMed ID: 7039729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for electrophilic properties of N2-methyl-9-hydroxy ellipticinium acetate (Celiptium) from human biliary metabolites.
    Bernadou J; Monsarrat B; Roche H; Armand JP; Paoletti C; Meunier B
    Cancer Chemother Pharmacol; 1985; 15(1):63-5. PubMed ID: 4006051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of 11H-pyridocarbazoles and derivatives. Comparison of their DNA binding and antitumor activity with those of 6H- and 7H-pyridocarbazoles.
    Lescot E; Muzard G; Markovits J; Belleney J; Roques BP; Le Pecq JB
    J Med Chem; 1986 Sep; 29(9):1731-7. PubMed ID: 3746819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.